Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations

References

• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• AlivertiARodgerKDellacaRLEffect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPDThorax2005601191692415994253
   PubMed Web of Science ®Google Scholar
• O’DonnellDLamMWebbKASpirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1999160254254910430726
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [online]2011 Available from: http://www.goldcopd.org/Accessed September 25, 2012
   Google Scholar
• JonesPWBoshTKQuality of life changes in COPD patients treated with salmeterolAm J Respir Crit Care Med19971554128312899105068
   PubMed Web of Science ®Google Scholar
• NiewoehnerDECollinsDErblandMLRelation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study GroupAm J Respir Crit Care Med20001614 Pt 11201120510764312
   PubMed Web of Science ®Google Scholar
• VestboJPauwelsRAndersonJAJonesPCalverleyPEarly onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary diseaseThorax200560430130415790985
   PubMed Web of Science ®Google Scholar
• JonesPDonohueJNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726822033040
   PubMed Web of Science ®Google Scholar
• Standardization of spirometry, 1994 update. American Thoracic SocietyAm J Respir Crit Care Med19951523110711367663792
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• JonesPWInterpreting thresholds for a clinically significant change in health status in asthma and COPDEur Respir J200219339840411936514
   PubMed Web of Science ®Google Scholar
• CalverleyPMSpencerSWillitsLBurgePSJonesPWGroup IOSLDEWithdrawal from treatment as an outcome in the ISOLDE study of COPDChest200312441350135614555565
   PubMed Web of Science ®Google Scholar
• CalverleyPMAlbertPWalkerPPBronchodilator reversibility in chronic obstructive pulmonary disease: use and limitationsLancet Respir Med20131756457324461617
   PubMed Web of Science ®Google Scholar
• JonesPWSt George’s respiratory questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseNew Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• MakeBJErikssonGCalverleyPMA score to predict short-term risk of COPD exacerbations (SCOPEX)Int J COPD201510201209
   Google Scholar
• WanESDeMeoDLHershCPClinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD)Respir Med2011105458859421145719
   PubMed Web of Science ®Google Scholar
• Al-aniSSpigtMHofsetPMelbyeHPredictors of exacerbations of asthma and COPD during one year in primary careFamily Pract2013306621628
   Web of Science ®Google Scholar
• AlbertPAgustiAEdwardsLBronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary diseaseThorax201267870170822696176
   PubMed Web of Science ®Google Scholar
• StevensonNJWalkerPPCostelloRWCalverleyPMLung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005172121510151616166620
   PubMed Web of Science ®Google Scholar
• SpencerSCalverleyPMBurgePSJonesPWImpact of preventing exacerbations on deterioration of health status in COPDEur Respir J200423569870215176682
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• KestenSPlautzMPiquetteCAHabibMPNiewoehnerDEPremature discontinuation of patients: a potential bias in COPD clinical trialsEur Respir J200730589890617690120
   PubMed Web of Science ®Google Scholar